Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1219167
- By:
- Publication type:
- Article
Works matching AU Zeng, Liangyu
Results: 4
1
2
PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
- Published in:
- 2023
- By:
- Publication type:
- Abstract
3
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3227
- By:
- Publication type:
- Article
4
Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases.
- Published in:
- Oncology Letters, 2025, v. 29, n. 2, p. N.PAG, doi. 10.3892/ol.2024.14817
- By:
- Publication type:
- Article